THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company developing Tcelna® (imilecleucel-T), a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced its addition to the Russell Microcap® Index. Effective today, Opexa joins the index following an annual reconstitution of the 4,000 largest U.S. stocks as of the end of May.
Help employers find you! Check out all the jobs and post your resume.
